90 related articles for article (PubMed ID: 25888568)
1. Interleukin-2-inducible T-cell kinase (ITK) targeting by BMS-509744 does not affect cell viability in T-cell prolymphocytic leukemia (T-PLL).
Dondorf S; Schrader A; Herling M
J Biol Chem; 2015 Apr; 290(16):10568-9. PubMed ID: 25888568
[No Abstract] [Full Text] [Related]
2. Targeting interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK) using a novel covalent inhibitor PRN694.
Zhong Y; Dong S; Strattan E; Ren L; Butchar JP; Thornton K; Mishra A; Porcu P; Bradshaw JM; Bisconte A; Owens TD; Verner E; Brameld KA; Funk JO; Hill RJ; Johnson AJ; Dubovsky JA
J Biol Chem; 2015 Mar; 290(10):5960-78. PubMed ID: 25593320
[TBL] [Abstract][Full Text] [Related]
3. 5-Aminomethyl-1H-benzimidazoles as orally active inhibitors of inducible T-cell kinase (Itk).
Winters MP; Robinson DJ; Khine HH; Pullen SS; Woska JR; Raymond EL; Sellati R; Cywin CL; Snow RJ; Kashem MA; Wolak JP; King J; Kaplita PV; Liu LH; Farrell TM; DesJarlais R; Roth GP; Takahashi H; Moriarty KJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5541-4. PubMed ID: 18823779
[TBL] [Abstract][Full Text] [Related]
4. A negative role for the interleukin-2-inducible T-cell kinase (ITK) in human Foxp3+ TREG differentiation.
Mamontov P; Eberwine RA; Perrigoue J; Das A; Friedman JR; Mora JR
PLoS One; 2019; 14(4):e0215963. PubMed ID: 31022269
[TBL] [Abstract][Full Text] [Related]
5. Covalent inhibitors of interleukin-2 inducible T cell kinase (itk) with nanomolar potency in a whole-blood assay.
Zapf CW; Gerstenberger BS; Xing L; Limburg DC; Anderson DR; Caspers N; Han S; Aulabaugh A; Kurumbail R; Shakya S; Li X; Spaulding V; Czerwinski RM; Seth N; Medley QG
J Med Chem; 2012 Nov; 55(22):10047-63. PubMed ID: 23098091
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent inhibitors of interleukin-2 inducible T-cell kinase (ITK) through structure-based drug design.
Cook BN; Bentzien J; White A; Nemoto PA; Wang J; Man CC; Soleymanzadeh F; Khine HH; Kashem MA; Kugler SZ; Wolak JP; Roth GP; De Lombaert S; Pullen SS; Takahashi H
Bioorg Med Chem Lett; 2009 Feb; 19(3):773-7. PubMed ID: 19111460
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel (4 or 5-aryl)pyrazolyl-indoles as inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Velankar AD; Quintini G; Prabhu A; Weber A; Hunaeus G; Voland B; Wuest M; Orjeda C; Harel D; Varghese S; Gore V; Patil M; Gayke D; Herdemann M; Heit I; Zaliani A
Bioorg Med Chem; 2010 Jun; 18(12):4547-59. PubMed ID: 20472447
[TBL] [Abstract][Full Text] [Related]
8. Design, synthesis and structure-activity relationship of indolylindazoles as potent and selective covalent inhibitors of interleukin-2 inducible T-cell kinase (ITK).
Wang X; Xue G; Pan Z
Eur J Med Chem; 2020 Feb; 187():111918. PubMed ID: 31830635
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
Tang G; Liu L; Wang X; Pan Z
Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
[TBL] [Abstract][Full Text] [Related]
10. Selective Itk inhibitors block T-cell activation and murine lung inflammation.
Lin TA; McIntyre KW; Das J; Liu C; O'Day KD; Penhallow B; Hung CY; Whitney GS; Shuster DJ; Yang X; Townsend R; Postelnek J; Spergel SH; Lin J; Moquin RV; Furch JA; Kamath AV; Zhang H; Marathe PH; Perez-Villar JJ; Doweyko A; Killar L; Dodd JH; Barrish JC; Wityak J; Kanner SB
Biochemistry; 2004 Aug; 43(34):11056-62. PubMed ID: 15323564
[TBL] [Abstract][Full Text] [Related]
11. itk, a T-cell-specific tyrosine kinase gene inducible by interleukin 2.
Siliciano JD; Morrow TA; Desiderio SV
Proc Natl Acad Sci U S A; 1992 Dec; 89(23):11194-8. PubMed ID: 1280821
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of the IL-2-inducible tyrosine kinase (Itk) activity: a new concept for the therapy of inflammatory skin diseases.
von Bonin A; Rausch A; Mengel A; Hitchcock M; Krüger M; von Ahsen O; Merz C; Röse L; Stock C; Martin SF; Leder G; Döcke WD; Asadullah K; Zügel U
Exp Dermatol; 2011 Jan; 20(1):41-7. PubMed ID: 21158938
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and structure-activity relationships of a novel class of sulfonylpyridine inhibitors of Interleukin-2 inducible T-cell kinase (ITK).
Trani G; Barker JJ; Bromidge SM; Brookfield FA; Burch JD; Chen Y; Eigenbrot C; Heifetz A; Ismaili MHA; Johnson A; Krülle TM; MacKinnon CH; Maghames R; McEwan PA; Montalbetti CAGN; Ortwine DF; Pérez-Fuertes Y; Vaidya DG; Wang X; Zarrin AA; Pei Z
Bioorg Med Chem Lett; 2014 Dec; 24(24):5818-5823. PubMed ID: 25455497
[TBL] [Abstract][Full Text] [Related]
14. Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 - 2013).
Norman P
Expert Opin Ther Pat; 2014 Sep; 24(9):979-91. PubMed ID: 24990480
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of interleukin-2 inducible T-cell kinase as potential therapeutic candidates for the treatment of various inflammatory disease conditions.
Kaur M; Bahia MS; Silakari O
Eur J Pharm Sci; 2012 Oct; 47(3):574-88. PubMed ID: 22820564
[TBL] [Abstract][Full Text] [Related]
16. Efficient CD28 signalling leads to increases in the kinase activities of the TEC family tyrosine kinase EMT/ITK/TSK and the SRC family tyrosine kinase LCK.
Gibson S; Truitt K; Lu Y; Lapushin R; Khan H; Imboden JB; Mills GB
Biochem J; 1998 Mar; 330 ( Pt 3)(Pt 3):1123-8. PubMed ID: 9494076
[TBL] [Abstract][Full Text] [Related]
17. Itk, a T cell-specific tyrosine kinase, is required for CD2-mediated interleukin-2 promoter activation in the human T cell line Jurkat.
Tanaka N; Abe H; Yagita H; Okumura K; Nakamura M; Sugamura K
Eur J Immunol; 1997 Apr; 27(4):834-41. PubMed ID: 9130632
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-2-Inducible T-Cell Kinase Deficiency Impairs Early Pulmonary Protection Against
Huang L; Ye K; McGee MC; Nidetz NF; Elmore JP; Limper CB; Southard TL; Russell DG; August A; Huang W
Front Immunol; 2019; 10():3103. PubMed ID: 32038633
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of IL-2 inducible T-cell kinase alleviates T-cell activation and murine myocardial inflammation associated with CVB3 infection.
He F; Yao H; Xiao Z; Han J; Zou J; Liu Z
Mol Immunol; 2014 May; 59(1):30-8. PubMed ID: 24462896
[TBL] [Abstract][Full Text] [Related]
20. Translocation-generated ITK-FER and ITK-SYK fusions induce STAT3 phosphorylation and CD69 expression.
Fathi NN; Mohammad DK; Görgens A; Andaloussi SE; Zain R; Nore BF; Smith CIE
Biochem Biophys Res Commun; 2018 Oct; 504(4):749-752. PubMed ID: 30217447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
